Last reviewed · How we verify
Topical IOP-lowering drugs — Competitive Intelligence Brief
phase 3
Topical IOP-lowering agents
Ophthalmology
Small molecule
Live · refreshed every 30 min
Target snapshot
Topical IOP-lowering drugs (Topical IOP-lowering drugs) — Bayer. Topical IOP-lowering drugs work by reducing intraocular pressure through the reduction of aqueous humor production or increase in aqueous humor outflow.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Topical IOP-lowering drugs TARGET | Topical IOP-lowering drugs | Bayer | phase 3 | Topical IOP-lowering agents |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape (Topical IOP-lowering agents class)
- Bayer · 1 drug in this class
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Topical IOP-lowering drugs CI watch — RSS
- Topical IOP-lowering drugs CI watch — Atom
- Topical IOP-lowering drugs CI watch — JSON
- Topical IOP-lowering drugs alone — RSS
- Whole Topical IOP-lowering agents class — RSS
Cite this brief
Drug Landscape (2026). Topical IOP-lowering drugs — Competitive Intelligence Brief. https://druglandscape.com/ci/topical-iop-lowering-drugs. Accessed 2026-05-18.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab